President Obama will nominate Rob Califf, current deputy commissioner for medical products and tobacco, as FDA commissioner.
A White House press statement reports that President Barack Obama intends to nominate Rob Califf as commissioner of Food and Drugs, Department of Health and Human Services.
Rob Califf currently is deputy commissioner for Medical Products and Tobacco at FDA, a position he has held since March 2015. He served in various capacities at Duke University School of Medicine and the Duke University Medical Center between 1982 and 2015 including director of the Duke Translational Medicine Institute, which he founded in 2006, and as professor of medicine at the medical center. He also served as the director of the cardiac care unit. He founded the Duke University Clinical Research Institute in 2006 and served as its director.
He has served in a number professional organizations, including committees of the Institute of Medicine of the National Academies (IOM), the IOM Clinical Research Roundtable, the IOM Committee on Medication Errors, and the IOM Board on Health Sciences Policy. He served on the FDA’s cardio renal advisory committee from 1996 to 2000 and on the FDA’s Science Board Working Group from 2007 to 2008. Califf holds a bachelor of science and doctor of medicine degrees from Duke University.
Stephen Ostroff, MD, has served as acting commissioner of FDA since former FDA commissioner Margaret A. Hamburg stepped down earlier this year following six years in the position.
Source: The White House, Office of the Press Secretary
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.